The hypothesis posits that crocetin, beyond its Nrf2‑activating effects, directly inhibits the Fe2+/2‑oxoglutarate‑dependent prolyl hydroxylase domain (PHD) enzymes that target HIF‑1α for proteasomal degradation. By chelating the catalytic Fe2+ ion through its conjugated polyene chain, crocetin stabilizes HIF‑1α even under normoxic conditions, triggering a transcriptional program that upregulates erythropoietin (EPO), vascular endothelial growth factor (VEGF), and glycolytic enzymes. This hypoxic‑response cascade complements Nrf2‑mediated antioxidant defenses, improving mitochondrial oxygen utilization and reducing ROS in aged neurons 1. The hypothesis predicts that (1) crocetin will increase nuclear HIF‑1α and downstream gene expression in primary cortical neurons exposed to normoxia, an effect abolished by Fe2+ supplementation or PHD over‑expression; (2) co‑administration of a BBB‑penetrating enhancer (e.g., γ‑cyclodextrin) will be required to achieve brain concentrations sufficient for PHD inhibition in vivo; and (3) genetic or pharmacological blockade of HIF‑1α will attenuate crocetin‑induced improvements in mitochondrial respiration and behavioral outcomes in aged mice, whereas Nrf2 loss will only partially affect these benefits.

To test the first prediction, primary cortical neurons from young adult mice will be treated with crocetin (0.1‑10 µM) for 6 h under normoxic (21% O2) conditions. Nuclear HIF‑1α levels will be measured by western blot and immunofluorescence, while HIF‑1α target mRNAs (Epo, Vegfa, Glut1) will be quantified by qPCR. Parallel cultures will receive Fe2+ ammonium sulfate (50‑200 µM) or adenoviral PHD2 over‑expression to rescue hydroxylase activity. A significant rise in nuclear HIF‑1α and target transcripts that is reversed by Fe2+ or PHD2 over‑expression would support direct PHD inhibition.

For the second prediction, aged mice (24‑26 months) will receive oral crocetin (50 mg/kg) either alone or complexed with γ‑cyclodextrin (1:2 molar ratio) once daily for 14 days. Brain crocetin concentrations will be quantified by LC‑MS/MS at 1 h post‑dose. HIF‑1α stabilization and target gene expression will be assessed in hippocampal and cortical tissue. Only the γ‑cyclodextrin group is expected to show brain crocetin levels above the estimated IC50 for PHD inhibition (≈1 µM) and concomitant HIF‑1α activation 345.

The third prediction will be examined using HIF‑1α floxed mice crossed with Camk2a‑Cre to delete HIF‑1α in forebrain neurons, and Nrf2 knockout mice. Both genotypes and wild‑type litterns will receive the γ‑cyclodextrin‑crocetin regimen. Mitochondrial respiration will be measured ex vivo using high‑resolution respirometry (OXPHOS capacity, coupling efficiency). Behavioral assays (Morris water maze, elevated plus maze) will evaluate memory and anxiety. If HIF‑1α deletion blunts the crocetin‑induced rise in OXPHOS capacity and improves memory, while Nrf2 loss yields a smaller effect, the data would indicate that HIF‑1α contributes significantly to crocetin’s neuroprotective action beyond Nrf2 2.

A falsifiable outcome would be the observation that crocetin fails to increase nuclear HIF‑1α or its targets even with BBB enhancement, or that HIF‑1α blockade does not alter crocetin‑mediated mitochondrial or behavioral benefits. Such results would refute the proposed PHD‑inhibitory mechanism and reinforce the view that crocetin acts solely through Nrf2‑dependent pathways.